This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hong, Y.
Right arrow Articles by McLachlan, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hong, Y.
Right arrow Articles by McLachlan, A. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2006, p. 935-942, Vol. 50, No. 3
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.3.935-942.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Population Pharmacokinetics of Liposomal Amphotericin B in Pediatric Patients with Malignant Diseases

Ying Hong,1,{dagger} Peter J. Shaw,2 Christa E. Nath,3 Satya P. Yadav,2 Katherine R. Stephen,2 John W. Earl,3 and Andrew J. McLachlan1*

Faculty of Pharmacy, University of Sydney,1 Department of Oncology,2 Department of Biochemistry, the Children's Hospital at Westmead, Sydney, NSW, Australia3

Received 21 June 2005/ Returned for modification 30 September 2005/ Accepted 27 December 2005

A population pharmacokinetic model of liposomal amphotericin B (L-AmB) in pediatric patients with malignant diseases was developed and evaluated. Blood samples were collected from 39 pediatric oncology patients who received multiple doses of L-AmB with a dose range from 0.8 to 5.9 mg/kg of body weight/day. The patient cohort had an average age of 7 years (range, 0.2 to 17 years) and weighed an average of 28.8 ± 19.8 kg. Population pharmacokinetic analyses were performed with NONMEM software. Pharmacokinetic parameters, interindividual variability (IIV), between-occasion variability (BOV), and intraindividual variability were estimated. The influence of patient characteristics on the pharmacokinetics of L-AmB was explored. The final population pharmacokinetic model was evaluated by using a bootstrap sampling technique. The L-AmB plasma concentration-time data was described by a two-compartment pharmacokinetic model with zero-order input and first-order elimination. The population mean estimates of clearance (CL) and volume of distribution in the central compartment (V1) were 0.44 liters/h and 3.12 liters, respectively, and exhibited IIV (CL, 10%) and significant BOV (CL, 46% and V1, 56%). The covariate models were CL (liters/h) = 0.44 · e0.0152 ·(WT – 21) and V1 (liters) = 3.12 · e0.0241 · (WT – 21), where WT is the patient's body weight (kg) centered on the study population cohort median of 21 kg. Model evaluation by the bootstrap procedure indicated that the full pharmacokinetic model was robust and parameter estimates were accurate. In conclusion, the pharmacokinetics of L-AmB in pediatric oncology patients were adequately described by the developed population model. The model has been evaluated and can be used in the design of rational dosing strategies for L-AmB antifungal therapy in this special population.

* Corresponding author. Mailing address: Faculty of Pharmacy, Pharmacy Building (A15), Camperdown Campus, University of Sydney, Sydney, NSW 2006, Australia. Phone: 61 2 9351 4452. Fax: 61 2 9351 4391. E-mail: andrewm{at}pharm.usyd.edu.au.

{dagger} Present address: Department of Pharmaceutical Sciences, University at Buffalo, SUNY.

Antimicrobial Agents and Chemotherapy, March 2006, p. 935-942, Vol. 50, No. 3
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.3.935-942.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Segal, B. H. (2009). Aspergillosis. NEJM 360: 1870-1884 [Full Text]  
  • Andes, D., Pascual, A., Marchetti, O. (2009). Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications. Antimicrob. Agents Chemother. 53: 24-34 [Full Text]  
  • Goodwin, M. L., Drew, R. H. (2008). Antifungal serum concentration monitoring: an update. J Antimicrob Chemother 61: 17-25 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»